Popular Articles

Statement By Merck & Co., Inc. Regarding FOSAMAX® (alendronate Sodium) And Rare Cases Of Osteonecrosis Of The Jaw
Merck is committed to putting patients first and providing accurate information regarding the efficacy, safety and tolerability of our medicines. Merck offers the following statement concerning the osteoporosis medication FOSAMAX® (alendronate sodium) and reports of jaw problems associated with delayed healing and infection of the jaw often following tooth extraction. The condition is known as osteonecrosis of the jaw (ONJ).
pharmacy online
Vertex Initiates Phase 3 Registration Program For VX-770, An Oral CFTR Potentiator Targeting The Defective Protein Responsible For Cystic Fibrosis
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the initiation of a Phase 3 registration program for VX-770, an investigational Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) potentiator that targets the defective CFTR protein that causes cystic fibrosis (CF). The VX-770 registration program will consist of three clinical trials, including a primary 48-week Phase 3 trial that is currently open to enrollment of patients aged 12 years and older who carry the G551D mutation on at least one allele. Two additional trials will evaluate VX-770 in patients aged 6 to 11 years with the G551D mutation on at least one allele and in patients homozygous for the F508del mutation, respectively.
News of the day
Gene Hunters Target Child Kidney Failure
Researchers are zeroing in on the genetic abnormalities predisposing to vesicoureteric reflux (VUR), one of the most common causes of urinary tract infections and kidney failure in children, reports a study in an upcoming issue of the Journal of the American Society of Nephrology (JASN). "In this study, we accomplished a very critical step towards the identification of the VUR gene," says Ali G. Gharavi, MD (Columbia University, New York).
Mental Health

The Emotional Cost Of Nursing

What are the costs of caring? A new project in the School of Psychology explores nurses" experience of distress and aims to determine if empathy with patients is associated with traumatic experience in nurses. Researcher Jenny Watts said nurses can develop symptoms such as flashbacks, sleeping difficulty and emotional detachment which can have serious consequences for both their personal and professional lives. She will be presenting her research at the Festival of Postgraduate Research which is taking place on Thursday 25th June in the Belvoir Suite, Charles Wilson Building at the University of Leicester between 11.30am and 1pm. Miss Watts said: "What is apparent is that nurses who identify with the patient and experience empathy appear to be most vulnerable to distress. "Nursing is a diverse specialty and patient condition and contact will vary greatly between different wards. Currently the research focuses upon surgery, accident and emergency and children"s wards "Nurses caring for patients with dementia and other age related illnesses have shown anxiety and depression following patient deterioration and death. "Further knowledge about nurse distress is required to shape interventions, reduce staff turnover, improve morale and maintain a high quality of care. "This knowledge will be applied to shape suitable prevention and intervention strategies." Miss Watts added that with a growing number of patients aged over 70, it was important to ensure that the nursing force remains healthy, compassionate and able to provide high quality care for older adults, Miss Watts studied BSc psychology at the University of Stirling, in Scotland. After work experience gained within the National Health Service and Social Services she became intrigued by positive psychology and specifically research aiming to enhance the wellbeing of health professionals. Leicester University


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):